Search

OBJECTIVES: The REAC-TAVI (Assessment of platelet REACtivity after Transcatheter Aortic Valve Implantation) trial enrolled patients with aortic stenosis (AS) undergoing transcatheter aortic valve replacement (TAVR) pre-treated with aspirin + clopidogrel, aimed to compare the efficacy of clopidogrel and ticagrelor in suppressing high platelet reactivity (HPR) after TAVI. BACKGROUND: Current recommendations support short-term use of aspirin + clopidogrel for patients with severe AS undergoing TAVR despite the lack of compelling evidence. METHODS: This was a prospective, randomized, multicenter investigation. Platelet reactivity was measured at 6 different time points with the VerifyNow assay (Accriva Diagnostics, San Diego, California). HPR was defined as (P2Y12 reaction units (PRU) ≥208. Patients with HPR before TAVR were randomized to either aspirin + ticagrelor or aspirin + clopidogrel for 3 months. Patients without HPR continued with aspirin + clopidogrel (registry cohort). The primary endpoint was non-HPR status (PRU

Management of the airframe digital twin (DT) and its real equivalent for reliability, safety and economic considerations requires, as one component, a probabilistic treatment of the fracture critical components. The computation of the probability-of-failure, the remaining useful life, and the effects of inspections and repairs require accurate and efficient fracture mechanics lifing analyses, probabilistic descriptions of inputs, and probabilistic algorithms. The required computations, the current state-of-the-art in the risk assessment of DT modeling, and future challenges are described. Numerical examples are presented to demonstrate the computations.

We have read the recently published paper from Baber et al. [(1)][1]. We would like to congratulate the authors for their excellent work, with the aim to integrate both risks (ischemic and hemorrhagic) in the same population. However, we have several concerns: First, the PARIS (Patterns of Non